Save Product
Product Details
Source
Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63) is a mouse monoclonal antibody recombinantly expressed from human 293 cells (HEK293), which provides higher batch consistency and long term security of supply.
Application
Flow Cytometry (Detection the expression of CD19 on Human cells).
Clone
FMC63
Species
Mouse
Isotype
Mouse IgG2a | Mouse kappa
Specificity
This product is a specific antibody specifically reacts with CD19 protein.
Reactivity
Human
Immunogen
Human prolymphocytic leukaemia cell line JVM3
Conjugate
FITC
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 535 nm
Recommended Dilution
1:50
Formulation
Supplied as 0.2 μm filtered solution in PBS, 0.03% Proclin 300, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Storage
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 12 months under sterile conditions.
Shipping
This product is supplied and shipped with blue ice, please inquire the shipping cost.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-FACS
Flow cytometric analysis of Human peripheral blood lymphocytes staining with FITC-Labeled Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63) (Cat. No. CD9-FM7A1) at 1:50 dilution (2 μL of the antibody stock solution corresponds to labeling of 1e6 cells in a final volume of 100 µL), compared with isotype control antibody. FITC signal was used to evaluate the binding activity (QC tested).
Protocol
Flow cytometric analysis of Human peripheral blood lymphocytes staining with PE anti-human CD3 antibody and FITC-Labeled Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63) (Cat. No. CD9-FM7A1) at 1:50 dilution (2 μL of the antibody stock solution corresponds to labeling of 1e6 cells in a final volume of 100 µL). FITC signal was used to evaluate the binding activity (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
B-lymphocyte antigen CD19
- Category：
- Approved Drugs：
12 Details
- Drugs in Clinical Trials：
310 Details
- Highest Development Stage：
NDA/BLA
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing